Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors

Despite the development of potent RAF/mitogen-activated protein kinase (MAPK) pathway inhibitors, only a fraction of BRAF-mutant patients benefit from treatment with these drugs. Using a combined chemogenomics and chemoproteomics approach, we identify drug-induced RAS-RAF-MEK complex formation in a...

Full description

Bibliographic Details
Main Authors: Martin L. Sos, Rebecca S. Levin, John D. Gordan, Juan A. Oses-Prieto, James T. Webber, Megan Salt, Byron Hann, Alma L. Burlingame, Frank McCormick, Sourav Bandyopadhyay, Kevan M. Shokat
Format: Article
Language:English
Published: Elsevier 2014-08-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124714005774

Internet

http://www.sciencedirect.com/science/article/pii/S2211124714005774

Similar Items